Amarjit Singh, MD
Family Medicine · Las Vegas, NVNPI 1982890539
Payments from drug & device makers
Across 25 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$144
- Smith+Nephew$133
- Mannkind Corporation$67
- Grifols USA, LLC$45
- Novo Nordisk$30
- Electromed, Inc.$23
- plus $49 from 3 others
What the payments were for
- Food & beverage$44991%
- Education$439%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 5 | $144 |
| Smith+Nephew | 9 | $133 |
| Mannkind Corporation | 2 | $67 |
| Grifols USA, LLC | 2 | $45 |
| Novo Nordisk | 2 | $30 |
| Electromed, Inc. | 2 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $14 |
How this compares
$491 in reported general payments places this provider in the 55th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 39 | $46,646 |
| EliquisApixaban | 103 | $30,227 |
| JardianceEmpagliflozin | 13 | $22,899 |
| XareltoRivaroxaban | 12 | $3,683 |
| Atorvastatin Calcium | 171 | $2,698 |
| Pantoprazole Sodium | 88 | $2,014 |
| Gabapentin | 63 | $1,990 |
| Tamsulosin Hcl | 54 | $1,421 |
| Enoxaparin Sodium | 28 | $1,415 |
| Levetiracetam | 37 | $1,204 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $1,191 |
| Hydralazine Hcl | 49 | $1,114 |
| ClopidogrelClopidogrel Bisulfate | 46 | $1,079 |
| Donepezil Hcl | 13 | $1,044 |
| Amlodipine Besylate | 86 | $1,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $30 | $46,64639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 902 family medicine providers in Nevada.
Other family medicine in Las Vegas
- Rogelio MachucaLas Vegas$3.3M
- Maxine InghamLas Vegas$2.9M
- Elliot ShinLas Vegas$2.1M
- Robert KaplanLas Vegas$1.7M
- Sean SuLas Vegas$1.1M
- Naz WahabLas Vegas$735K
- Carmelo RilleraLas Vegas$531K
- Peter PhilanderLas Vegas$524K
- Jerry CadeLas Vegas$381K
- Dana ForteLas Vegas$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.